cyrilzakka/clinical-trials huggingface dataset:
A Randomized Controlled Trial of a Multicomponent Walking Aid Program for People With MS

This is a randomized controlled trial of the Assistive Device Selection, Training, and Education Program (ADSTEP). ADSTEP is a training program of six weekly one-on-one sessions with a physical therapist intended to reduce falls among people who use a hand-held walking aid, such as a cane or a walker. ADSTEP focuses on training in the use of the walking aid, and includes gait evaluation, walking aid selection and fitting, and progressive task-oriented training with the walking aid.

Participants will be randomized to receive ADSTEP or a waitlist control intervention; those in the control condition will receive National MS Society brochures on fall prevention and walking aid selection, and a letter will be sent informing their care provider that the subject reports falling. All subjects will complete an assessment visit at baseline, and follow-up assessments at about 8 weeks and about 6 months after that. Subjects will complete paper questionnaires of patient reported outcomes (PROs), a modified Functional Gait Assessment / Dynamic Gait Index, and will track fall sustained over their participation in the study using monthly paper fall calendars. At the end of study participation, all subjects in the control group will be offered the opportunity to receive ADSTEP.


Eligibility Criteria:
Inclusion Criteria:

1. A definite diagnosis of MS of any type;
2. 18 years of age or older;
3. Self-reported history of at least one fall in the previous year;
4. Ability to walk at least 25 feet with or without an assistive device;
5. Intermittent or constant unilateral or bilateral assistance required to walk;
6. No MS exacerbations for the past 30 days;
7. Willingness to complete a written daily record of falls for about 8 months.

Exclusion Criteria:

1. Currently receiving physical therapy, or having any plans to receive physical therapy in the upcoming 8 months (duration of study participation);
2. Serious psychiatric or medical conditions that would preclude reliable participation in the study (e.g. dementia, deafness, blindness);
3. Inability to follow directions in English.
99mTc-P137 SPECT/CT in Prostate Cancer

Purpose: This study will take prostate specific membrane antigen (PSMA) as the targeting of radionuclide labeled molecular probe to explore the diagnostic efficacy of 99mTc-P137 radioactive probe in prostate cancer. Combining with SPECT/CT to optimize the imaging, image analysis and clinical diagnosis process of 99mTc-P137 probe, the aim of the study is to provide new methods and new means for the early detection, early diagnosis, accurate tumor staging, treatment decision and prognosis judgment of malignant tumor, and will provide scientific and clinical basis for the precise diagnosis and treatment of prostate cancer.

Research objectives: To investigate the clinical translational application value of 99mTc-P137 molecular probe in accurate detection of prostate cancer lesions.

Research design: A prospective study design will be used in this study. Patients meeting the inclusion criteria of this study will be analyzed with 99mTc-P137 SPECT/CT imaging. To evaluate the diagnostic and prognostic value of 99mTc-P137 nuclear medicine imaging in accurate detection of prostate cancer lesions, clinical surgical specimens and pathological diagnosis will be used as the gold standard.

Study the population Indications: For patients with suspected prostate cancer who plan to undergo surgical resection or puncture biopsy after various examinations, the final pathological results can be obtained.


Eligibility Criteria:
Inclusion Criteria:

* patients age 18 or above;
* highly suspicious for prostate cancer patients: 1) Serum PSA is significantly changed compared with before (PSA\<4.0ng/mL with annual change \>0.35ng/mL; or PSA \> 4.0ng/mL with annual change \> 0.75ng/mL); 2) First or second degree relatives have a history of prostate cancer; 3) Nuclear magnetic PI-RADS score ≥3 points;
* the prostate biopsy or surgical pathology is diagnosed with prostate cancer;
* available to provide clinical laboratory results (blood routine, biochemical and serum PSA) within one month before this study; At least two imaging examinations including CT, MRI, nuclear medicine (PET/CT or SPECT/CT), ultrasound and other imaging techniques;
* Can complete the inspection autonomously;
* voluntary and signed informed consent.

Exclusion Criteria:

* there are other malignant tumor history;
* severe damage of liver and kidney function;
* may not be able to obtain pathology or long-term follow-up results;
* don't have access to relevant reference image data and clinical data;
* difficult to cooperate.
Quality of Life After Gynacological Malignancies

Evaluate quality of life after gynaecological malignancies diagnosis and treatment

gynecological cancers represent 10% of new cancer cases among women The main types are cervical, endometrial, ovarian and breast cancers. Each of these is unique in terms of prognosis, treatment, and age at onset.

Early detection and improvement in treatment of these cancers has led to improvements in survival and, consequently, an increase in the number of survivors However, survival is accompanied by several negative aspects, such as fatigue, physical changes, sexual dysfunction, anxiety, and/or depression In addition to the physical and psychological disorders, survivors of gynecological cancer can experience economic problems related to work, or access to loans and insurance Although cancer occurs mainly in older adults, some people, particularly survivors of cervical and ovarian cancer, may experience cancer at an age where work is still of major importance For these women, a return to work represents a return to a normal social life and helps them to regain their self-esteem. Furthermore, work is a source of emotional and financial support and has been shown to enhance health-related quality of life by its positive effect on self-esteem Therefore, special attention must be paid to the well-being of survivors of gynecological cancer, as well as to their social and professional reintegratio is a multidimensional concept which encom passes physical and mental health as well as social well being. Although in recent decades, several studies have focused on and its determinants in survivors of gynecological cancer, has mainly been studied as it pertains to clinical data or with short follow-up durations. Our previous studies in long-term survivors of breast cancer have shown that the likelihood that will depend on other factors increases in line with the length of follow-up since diagnosis.

Due to the improvement in medical science and continuing advancement in early detection and treatment, the expected survival time of cancer patients has become longer. This has resulted in an increased interest in exploring the health-related quality of life of cancer survivors. So, there is a consequent need to satisfy cancer patients' requirements which would enable them to live a healthy life In many cases, cancer patients experience sleep disturbance, depression and poor quality of life after being diagnosed and treated for cancer. So, the assessment of QoL among cancer patients is essential in order to design interventions for improving patients' outcomes Likewise, QoL assessment assists people realize how treatment, disease, and health impact quality of life. Furthermore, it helps to understand potential beneficial and risky aspects of a treatment thus help in weighing the impact of a decision

Eligibility Criteria:
Inclusion Criteria:.patient diagnosed to have gynaecological cancers by histopathology 2.Adult from 20-70 yrs 3. willing and able to participate 4.Early stage 1-2

Exclusion Criteria:

1pre-existing psychological disorders 2.Stage 4 3.severe medical complications as cardiac pt 4.Morbid obesity BMI\<40
Analysis of Different Postoperative Analgesia Strategies Following Scoliosis Surgery

Idiopathic scoliosis surgery is a major surgery, causing significant post-operative pain which can have a significant impact, both for the patient and for society. Different analgesic strategies have emerged in recent years, within the framework of multimodal analgesia including systemic analgesics, but also axial or peripheral loco-regional anesthesia (LRA). These techniques are integrated into the recommendations of learned societies, aimed at optimizing the post-operative rehabilitation of patients.

If intrathecal morphine injection (ITM) and spinal erector block (ESPB) have already shown their effectiveness in reducing postoperative pain, the combination of these techniques can have a real benefit in major spinal surgery. , and has not yet been studied.


Eligibility Criteria:
Inclusion Criteria:

* Patient aged \> 15 years
* Patient who underwent scoliosis surgery by the spine surgery team at Hautepierre hospital between January 1, 2020 and June 30, 2023
* Patient or holder of parental authority not opposing the reuse of their data for scientific research purposes

Exclusion Criteria:

* Oral or written refusal of the patient (or the holder of parental authority) to reuse their data for scientific research purposes
* History of spinal surgery
* Level 3 analgesics at home
* Protection of justice, titular or curatorship
Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL

The purposee of this study is to determine the safety and dosing of Fenretinide when given continuously for 5 days, every 3 weeks, in pediatric patients with recurrent and/or resistant acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), and non-Hodgkin's lymphoma (NHL).

Fenretinide is a cytotoxic retinoid that has activity against a variety of cell lines in vitro in a dose-related manner. The exact mechanism of fenretinide cytotoxicity in leukemia and lymphoma cell lines is not known, but may include the de novo ceramide synthesis of ceramides and the generation of reactive oxygen species. The malignancy-specific nature of fenretinide-induced ceramides suggests that combinations of the drug with other ceramide modulating agents may have a favorable therapeutic index.

In this study, the primary aims are to define the maximum tolerated dose, toxicity profile, and pharmacokinetics of IV fenretinide when given continuously in pediatric patients with ALL, AML, and NHL. The drug will be administered via a central venous or percutaneous indwelling central catheter in an inpatient hospital setting.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosed with relapsed or refractory ALL, AML, or NHL
* Must have had two or more therapeutic attempts for treating/curing disease
* Must have fully recoved from acute toxic effects of all prior therapy
* Karnofsky of greater than 50% for older than 10 years of age and Lansky greater than 50% for younger than 10 years.

Exclusion Criteria:

* Grade 2 Pruritus or Rash (all forms)
* Grade 3 Dry Skin that is refractory to topical medical management
* Cardiac Fractional Shortening \< 27% on echocardiogram
* Left Ventricular Ejection Fraction \< 45% on echocardiogram
* Known allergy to egg products or soy bean oil
* Renal, Liver, and Pancreatic function:

  * serum creatinine \> 1.5X ULN
  * direct bilirubin \> 1.5X ULN
  * ALT or AST \> 2.5X ULN
  * Serum trigylcerides \> 2.5X ULN for age
  * Lipase \> 1.5X ULN for age
* History of pancreatitis
Musculoskeletal Problems and Strategies Developed by Physiotherapists to Cope With Them

The aim of this study is to investigate whether there is a difference in areas such as occupational musculoskeletal injuries and strategies developed by physiotherapists working in different fields, burnout and occupational satisfaction.

This study is a descriptive, cross-sectional online survey study. In this study, it is aimed to reach people who have graduated from the Physiotherapy and Rehabilitation Departments of the Faculties of Health Sciences or the Physical Therapy and Rehabilitation Schools of universities in Turkey, which provide education for 4 years and have the title of "physiotherapist". Physiotherapists will be divided into 5 groups according to the fields they work. Group 1 is only pediatric patients, Group 2 is orthopedics and sportsman, Group 3 is neurology and intensive care, Group 4 is general group that receives patients in many fields, and Group 5 is physiotherapists working in the field of public health. planned to occur. Before starting the study, the participants will be asked to fill in the Volunteer and Consent Form that they voluntarily participated in, and then they will be asked to fill out the Personal Information Form, the Extended Nordic Musculoskeletal System Questionnaire, the Pain Coping Inventory, the Maslach Burnout Scale, and the Vocational Satisfaction Scale prepared by us. According to the results obtained, 5 different groups will be compared among themselves by the determined parameters. The surveys to be used will be uploaded to the Google Forms database. Then, the participants will be asked to participate in the study by being reached via online media such as e-mail, mobile phone applications , social media.

Eligibility Criteria:
Inclusion Criteria:

* Volunteering to participate in the study
* Being a physiotherapist
* Having completed at least 1 year in the profession and continuing an active working life
* Being between the ages of 21 and 60

Exclusion Criteria:

* Not having completed 1 year in the profession
* Having any systemic disease
Safety Study of a Bioresorbable Coronary Stent

To evaluate the safety of a new bioresorbable (non-permanent) stent platform in native coronary arteries.

Today, coronary artery disease is often treated by placing a metal stent inside the vessel that serves as a permanent scaffold. However, it is hypothesized that the stent is no longer needed once the artery has healed. This study will evaluate the safety of a bioresorbable (non-permanent) stent for the treatment of coronary artery disease. The stent is designed to restore blood flow to the artery which allows the artery to remodel (heal), and then resorb from the body. The stent supports the vessel during the critical 90-day healing process, and then gradually resorbs and is cleared from the body.

Eligibility Criteria:
Inclusion Criteria:

* Evidence of myocardial ischemia or a positive functional study.
* Normal CK-MB.
* Target lesion must be located in a native coronary artery where target vessel diameter is ≥ 2.9 mm and ≤ 3.3 mm and target lesion length is ≤ 12 mm, both assessed by on-line QCA and IVUS
* Target lesion must be in a major artery or branch with a visually estimated stenosis of ≥ 50% and \< 100% with a TIMI flow of ≥ 2.
* Staged procedures are allowed in non-target vessels \>24 hours before or \> 30 days after REVA stent implantation

Exclusion Criteria:

* A myocardial infarction (CK-MB or Troponin \> 3 times normal) within 72 hours of the procedure, has signs or symptoms of an ongoing myocardial infarction or has any visible thrombus
* Unprotected left main coronary disease with \>50% stenosis
* The target vessel is totally occluded (TIMI Flow 0 to 1)
* Target lesion involves a bifurcation (a lesion with a side branch \>2.0 mm in diameter containing a \>50% stenosis)
* Target lesion is located within a segment supplied by distal graft
* Target lesion has possible or definite thrombus
Percutaneous Endoscopic Gastrostomy Tube Placement by Otorhinolaryngologist

The investigators main endpoint was focused on the analysis of the type, rate and the impact of different clinical parameters on the complications of the PEG tube placements performed at the Department of Otorhinolaryngology - Head and Neck Surgery since October 2008. In addition, the investigators aimed to compare the results with a historic cohort patient group (September 2005 - October 2008) sent to the Department of Surgery for PEG tube placement in order to evaluate the results of the changed routine.

We retrospectively reviewed a cohort of patients that had undergone PEG tube placement from October 2008 until October 2010 at the Department of Otorhinolaryngology - Head and Neck Surgery, Helsinki University Central Hospital (HUCH), Helsinki, Finland, with a health care district currently including approximately 1.5 million inhabitants. Hospital surgical and discharge registries were used to identify the patients. Medical records were studied and details collected on the patients' age, sex, preoperative condition, preoperative laboratory parameters, coexisting medical diagnoses (Charlson Comorbidity Index, CCI (Hall 2004)), indication and date for PEG tube placement, complications, the time of PEG use, follow-up time, and clinical status at last follow up. The study period was aimed to run from PEG tube placement to the last clinical evaluation (minimum 12 months) or the time of death. These results were compared with those from a historic cohort group of patients with the PEG tube placed in the Department of Surgery, HUCH, Helsinki, Finland from September 2005 until October 2008.

Eligibility Criteria:
Inclusion Criteria:

* ENT patient with PEG tube placement

Exclusion Criteria:

* electrolyte imbalance
* coagulation imbalance
* morbid obesity (BMI \> 40 kg/m2)
* large volume ascites
* previous gastrectomy
* sepsis
STARflo European Safety and Efficacy Study

Prospective, Non-comparative, Multi-center clinical trial to evaluate the safety and efficacy of the STARflo Glaucoma Implant in patients with refractory open angle glaucoma.

This is a prospective, multicenter clinical trial to assess the efficacy and the safety of the STARflo™ Glaucoma Implant.

Patients will enter the study after providing written informed consent. Patients will be screened to confirm that they are eligible for study participation.

When eligibility has been established using the in/exclusion criteria, surgery will be scheduled.

Pre and post-surgery, patients will be evaluated at scheduled intervals (1 day, 1 week, 1 month, 3 months, 6 months, 12 months, 24 months) for a total duration of 24 months following surgery.

Eligibility Criteria:
Main Inclusion Criteria:

* Diagnosis of refractory open angle glaucoma
* Documented 21 mmHg \< IOP ≤ 40 mmHg, under medication
* Patient must provide written informed consent

Main Exclusion Criteria:

* Patients with diagnosis of glaucoma other than open angle glaucoma (e.g. angle closure glaucoma) in the study eye
* Patients who failed one or more cilio ablative procedure in the study eye if these cilio ablative procedures were performed as a consequence of previous failed filtering surgery
* Clinically significant intra-ocular inflammation or infection, presence of ocular disease such as uveitis, ocular infection, severe dry eye, severe blepharitis, active proliferative/inflammatory retinopathy in the study eye
The Role of Vasopressin Antagonism on Renal Sodium Handling

Vasopressin has primarily been considered to be a water and osmosis regulating hormone that mediates its effects on renal aquaporin channels. Recent data suggest that vasopressin, through its V2 receptor, may also modulate sodium homeostasis. The purpose of this human physiology study was to test whether antagonism of the V2R alters urine sodium excretion in normal healthy volunteers.

Vasopressin's potential roles in maintaining normal volume homeostasis are expanding. While previous data support the concept that vasopressin's primary role is in mediating water homeostasis, recent data suggest that vasopressin, through its V2 receptor, may also modulate sodium homeostasis. This effect occurs via activation of the epithelial sodium channel (ENaC). These studies document that vasopressin via activation of the V2 receptor, not only reduces free water excretion but also sodium excretion. These data suggest that blocking this receptor under the right circumstances and in the right population may be effective in modulating hypertension in humans: specifically a V2 receptor antagonist may be effective in treating some individuals that have salt-sensitive hypertension. The current proposal will test in normal human subjects the proof of principle of the above stated hypothesis, and to assess the best markers to determine such an effect. It is important to perform studies with strict environmental control in a clinical research center because of the variability of environmental factors that can create confusion in interpreting data (dietary sodium, activity, body posture, diurnal variation, ambient temperature, sleep-wake cycle, etc.).

The overall program objective is to determine if a vasopressin V2 antagonist will be an effective treatment for salt-sensitive hypertension and if so, what subtype. The object of this specific proposal is to determine the effect of a selective V2 antagonist on sodium handling in normal subjects.

Eligibility Criteria:
Inclusion Criteria:

* - Blood pressure \<130/85 mmHg and \>100/50 mmHg
* Normal laboratory values for (see "Normal Values" table):
* Complete blood count
* Serum creatinine, sodium, potassium, glucose, liver enzymes
* Urinalysis
* ECG

Exclusion Criteria:

* - Alcohol intake \>12 oz per week
* Tobacco or recreational drug use
* History of coronary disease, diabetes, hypertension, stroke, kidney disease, or illness requiring overnight hospitalization in the past 6 months
* Any prescription medication or herbal medication use except oral contraceptive or multivitamin
* Pregnancy or current breastfeeding
* First degree relative with hypertension, diabetes, stroke, renal or cardiac disease
Geriatric Locomotive Syndrome and Related Factors in Older Adults

It has been stated that the results of physical function and physical performance affecting locomotive syndrome in elderly individuals are controversial and studies are still needed. However, no studies have been found examining its relationship with the decrease in physical activity level, decline in cognitive functions, kinesiophobia (fear of movement) and fatigue seen in old age. Early detection of locomotive syndrome risk factors in elderly individuals will help prevent this condition, detect the risk of falling in elderly individuals and increase their quality of life. Based on these deficiencies, it is aimed to examine the relationship between locomotive syndrome and kinesiophobia, physical activity level, physical performance, fatigue and cognitive functions in elderly individuals.

It has been reported that problems related to the musculoskeletal system, such as osteoarthritis, osteoporosis or spondylosis, increase with aging in elderly individuals. The Japanese Orthopedic Association (JOA) has defined this condition as locomotive syndrome (LS) in elderly individuals, as a condition of decreased mobility due to deterioration of locomotive organs. LS is a condition of reduced mobility due to deterioration of locomotive organs. It has been stated that the results of physical function and physical performance affecting locomotive syndrome in elderly individuals are controversial and studies are still needed. However, no studies have been found examining its relationship with the decrease in physical activity level, decline in cognitive functions, kinesiophobia (fear of movement) and fatigue seen in old age. Early detection of locomotive syndrome risk factors in elderly individuals will help prevent this condition, detect the risk of falling in elderly individuals and increase their quality of life. Based on these deficiencies, it is aimed to examine the relationship between locomotive syndrome and kinesiophobia, physical activity level, physical performance, fatigue and cognitive functions in elderly individuals.

Eligibility Criteria:
Inclusion Criteria:

Individuals aged 65 and over, Volunteering to participate in research No cooperation and communication problems (Mini Mental State Test score above 24)

Exclusion Criteria:

Individuals with neurological and orthopedic problems

* Uncontrolled hypertension
* Those with cardiac disease
* Those with cooperation and communication problems